Edwards Current Deferred Revenue from 2010 to 2025

EW Stock  USD 69.78  0.08  0.11%   
Edwards Lifesciences Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue will likely drop to about 554.1 M in 2025. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2001-03-31
Previous Quarter
47 M
Current Value
66 M
Quarterly Volatility
398.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.7 M, Interest Expense of 10.6 M or Selling General Administrative of 2.1 B, as well as many indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0 or PTB Ratio of 4.82. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Edwards Lifesciences Corp over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Edwards Lifesciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Edwards Current Deferred Revenue Regression Statistics

Arithmetic Mean634,198,047
Coefficient Of Variation41.65
Mean Deviation132,311,846
Median633,100,000
Standard Deviation264,121,583
Sample Variance69760.2T
Range1.3B
R-Value0.55
Mean Square Error52351.8T
R-Squared0.30
Significance0.03
Slope30,364,355
Total Sum of Squares1046403.2T

Edwards Current Deferred Revenue History

2025554.1 M
20241.1 B
2023953.9 M
2022484 M
2021798.4 M
2020630.9 M

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 B554.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.